Search results
Results from the WOW.Com Content Network
LifeScan was established in 1981. [3] It was acquired by Johnson & Johnson (J&J) in 1986, [2] [4] and in June 2018, J&J agreed to sell LifeScan to Platinum Equity as part of its strategic exit from the diabetes device market, accepting an offer originally tendered in March 2018. [1]
The OneTouch Ultra 2 Meter is being used by a diabetic patient. OneTouch Ultra is a blood glucose monitoring device for people with diabetes that is manufactured by Johnson & Johnson . [ 1 ] It is the foundation product for LifeScan's OneTouch Ultra family of blood glucose monitoring systems .
The lenses lasted up to one week, reducing the cost of contact lenses. In the same year, the company launched One Touch, a blood glucose monitoring system. In 1989, Ralph S. Larsen was appointed chairman and CEO of the company. [60] After the dissolution of the Soviet Union, Johnson & Johnson expanded into eastern Europe.
This is a set category.It should only contain pages that are Diabetes-related supplies and medical equipment or lists of Diabetes-related supplies and medical equipment, as well as subcategories containing those things (themselves set categories).
As a program manager at Johnson & Johnson's blood glucose monitoring company, LifeScan, Douglas was part of the team that won the Shingo Prize for Operational Excellence in 1995. LifeScan was later purchased for $2.1 billion by the global investment firm Platinum Equity in 2018.
In 1998 dozens of federal agents raided the headquarters of Johnson & Johnson's LifeScan unit after it failed to notify the Food and Drug Administration of a software glitch in a diabetes diagnostic device that it manufactured. In 2000 LifeScan pleaded guilty to criminal charges and agreed to pay $60 million in fines for selling defective ...
A glucose meter, also referred to as a "glucometer", [1] is a medical device for determining the approximate concentration of glucose in the blood.It can also be a strip of glucose paper dipped into a substance and measured to the glucose chart.
The 29,800-square-foot facility features laboratories for blood, optical, software, mechanical and electrical research, plus a production line. [19] In 2019, Barron's ranked Abiomed the fourth best stock of the 2010s, with total return of 1,983%. [20] while Fortune ranked Abiomed 19th on the magazine's list of 100 fastest-growing companies. [21]